Introduction Advancements in hematopoietic cell transplantation (HCT) have been associated with expanding indications and eligibility, alternative donor options, and improvement in overall survival (OS). Yet, HCT for hematologic malignancies are still associated with the potential for significant toxicities that may…
Introduction Graft-versus-host disease (GVHD) is the leading cause of nonrelapse mortality (NRM) beyond day 100 in recipients of human leukocyte antigen (HLA)-matched sibling donor (MSD) hematopoietic cell transplantation (HCT), and the second leading cause of NRM in recipients of HLA-matched…
Introduction and Historical Perspective The first hematopoietic cell transplantation (HCT) was performed in 1956 and demonstrated neutrophil recovery and transient donor cell engraftment, as documented by red cell engraftment. However, in these original transplants only two of the six reported…
Infections are a frequent cause of morbidity and mortality in recipients of hematopoietic cell transplant (HCT). Multiple studies have documented a significant and progressive improvement in outcomes of recipients of HCT over the last two decades because of a decline…
Overview Hematopoietic cell transplant (HCT) recipients are at a heightened risk of a wide range of new infections or the reactivation of latent or remote infections given the extent of immunosuppression and immune dysregulation caused by chemotherapy, immunosuppressive medications for…
Background: Natural Killer Cell Biology In 1973, Ivan Roitt's laboratory identified a new class of lymphocytes dubbed “null” killer cells, since they were neither T-cells nor B cells. The following year, these “null” lymphocytes were found to have spontaneous ability…
Introduction to Germ-Cell Tumors Germ-cell tumors (GCT) are the most common malignancy in young men ages 15 to 35 years. These tumors have great response rates to cisplatin-based chemotherapy, with cure rates for metastatic disease as high as 70% to…
Introduction There is an expanding role for hematopoietic cell transplantation (HCT) in rare hematologic malignancies. The rarity of these diseases limit well-designed prospective trials. In this chapter, we review the available data on the role of allogeneic and autologous HCT…
Introduction Clinical trials of CD19 chimeric antigen receptor (CAR) T-cells have demonstrated promising survival outcomes and response rates in relapsed and/or refractory (r/r) non-Hodgkin lymphoma (NHL), providing a potentially curative treatment option for these heterogeneous, aggressive malignancies. There are currently…
Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. The disease has a bimodal distribution with an increased incidence in young…